Kadmon Holdings (Kadmon Holdings) EV-to-EBITDA : -15.38 (As of Apr. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Kadmon Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kadmon Holdings's enterprise value is $1,731.29 Mil. Kadmon Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2021 was $-112.55 Mil. Therefore, Kadmon Holdings's EV-to-EBITDA for today is -15.38.

The historical rank and industry rank for Kadmon Holdings's EV-to-EBITDA or its related term are showing as below:

KDMN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.38 Med: -5.91 Max: -1.13
Current: -15.38

During the past 7 years, the highest EV-to-EBITDA of Kadmon Holdings was -1.13. The lowest was -15.38. And the median was -5.91.

KDMN's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.22 vs KDMN: -15.38

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Kadmon Holdings's stock price is $9.50. Kadmon Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.720. Therefore, Kadmon Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Kadmon Holdings EV-to-EBITDA Historical Data

The historical data trend for Kadmon Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadmon Holdings EV-to-EBITDA Chart

Kadmon Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EV-to-EBITDA

Get a 7-Day Free Trial

-2.17

-3.92

-4.23

-10.72

-6.00

Kadmon Holdings Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
EV-to-EBITDA	Get a 7-Day Free Trial															-6.37	-6.00	-6.28	-6.40	-13.98

Competitive Comparison of Kadmon Holdings's EV-to-EBITDA

For the Biotechnology subindustry, Kadmon Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kadmon Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kadmon Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kadmon Holdings's EV-to-EBITDA falls into.

Kadmon Holdings EV-to-EBITDA Calculation

Kadmon Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	1731.288	/	-112.553
	=	-15.38

Kadmon Holdings's current Enterprise Value is $1,731.29 Mil.
Kadmon Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.55 Mil.

Kadmon Holdings (NAS:KDMN) EV-to-EBITDA Explanation

Kadmon Holdings's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	9.50	/	-0.720
	=	At Loss

Kadmon Holdings's share price for today is $9.50.
Kadmon Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.720.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Kadmon Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kadmon Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Kadmon Holdings (Kadmon Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadmon Holdings Inc (NAS:KDMN) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 East 29th Street, New York, NY, USA, 10016

Website

https://www.kadmon.com

Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.

Executives

Harlan Waksal	director, officer: President, CEO	WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Eugene Bauer	director	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016
Tasos Konidaris	director	103 JFK PARKWAY, SHORT HILLS NJ 07078
John L Ryan	officer: Executive Vice President, CMO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Steven Meehan	officer: EVP, Chief Financial Officer	450 E. 29TH STREET NEW YORK NY 10016
Kyle Carver	officer: Principal Accounting Officer, Controller	450 EAST 29TH STREET NEW YORK NY 10016
Gregory S. Moss	officer: EVP, General Counsel, Chief Compliance Officer	450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	other: Former 10% owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Steven N. Gordon	officer: Exec VP, GC, Chief Admin, Comp	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016